Information Provided By: 
Fly News Breaks for September 13, 2017
LLY
Sep 13, 2017 | 07:15 EDT
SunTrust analyst John Boris says that data on the efficacy of Eli Lilly's Jardiance drug showed that it " reduces risk of cardiovascular death in type 2 diabetes patients irrespective of background blood glucose levels." The analyst thinks the data supports the use of the drug "in various (type 2 diabetes) settings." He expects the company's diabetes business to reach $10.5B in 2021, up from $4.4B in 2013. Boris keeps a $96 price target and a Buy rating on the shares.
News For LLY From the Last 2 Days
LLY
Apr 19, 2024 | 12:01 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
LLY
Apr 19, 2024 | 06:17 EDT
